批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2011/05/02 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
STANDARD
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2023/06/20 |
SUPPL-27(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
PRIORITY
|
|
|
| 2022/04/15 |
SUPPL-25(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2020/03/30 |
SUPPL-20(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
| 2019/07/03 |
SUPPL-18(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
| 2019/07/01 |
SUPPL-21(补充) |
Approval |
Labeling-Package Insert |
901 REQUIRED
|
|
|
| 2017/08/10 |
SUPPL-16(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2017/03/14 |
SUPPL-14(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2016/12/23 |
SUPPL-15(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2016/12/20 |
SUPPL-13(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/08/28 |
SUPPL-12(补充) |
Approval |
Labeling-Package Insert |
901 REQUIRED
|
|
|
| 2015/07/28 |
SUPPL-11(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2015/07/20 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2014/05/22 |
SUPPL-9(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2013/06/18 |
SUPPL-6(补充) |
Approval |
Labeling-Package Insert |
UNKNOWN
|
|
|
| 2012/09/28 |
SUPPL-5(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
| 2012/08/13 |
SUPPL-4(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
| 2012/08/13 |
SUPPL-3(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
| 2012/05/22 |
SUPPL-2(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:LINAGLIPTIN; 剂型/给药途径:TABLET;ORAL; 规格:5MG; 治疗等效代码:AB<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 201280 |
001 |
NDA |
TRADJENTA |
LINAGLIPTIN |
TABLET;ORAL |
5MG |
Prescription |
Yes |
Yes |
AB |
2011/05/02
|
BOEHRINGER INGELHEIM |
| 208335 |
001 |
ANDA |
LINAGLIPTIN |
LINAGLIPTIN |
TABLET;ORAL |
5MG |
Prescription |
No |
No |
AB |
2021/08/31
|
SUNSHINE |
| 208448 |
001 |
ANDA |
LINAGLIPTIN |
LINAGLIPTIN |
TABLET;ORAL |
5MG |
Prescription |
No |
No |
AB |
2023/03/30
|
ZYDUS PHARMS |
| 208423 |
001 |
ANDA |
LINAGLIPTIN |
LINAGLIPTIN |
TABLET;ORAL |
5MG |
Prescription |
No |
No |
AB |
2024/09/03
|
INVAGEN PHARMS |
| 208428 |
001 |
ANDA |
LINAGLIPTIN |
LINAGLIPTIN |
TABLET;ORAL |
5MG |
Prescription |
No |
No |
AB |
2025/11/03
|
DR REDDYS |
| 208431 |
001 |
ANDA |
LINAGLIPTIN |
LINAGLIPTIN |
TABLET;ORAL |
5MG |
Prescription |
No |
No |
AB |
2025/11/03
|
MYLAN |
| 208415 |
001 |
ANDA |
LINAGLIPTIN |
LINAGLIPTIN |
TABLET;ORAL |
5MG |
Prescription |
No |
No |
AB |
2025/11/03
|
AUROBINDO PHARMA LTD |
| 208457 |
001 |
ANDA |
LINAGLIPTIN |
LINAGLIPTIN |
TABLET;ORAL |
5MG |
Prescription |
No |
No |
AB |
2025/11/03
|
MSN |